nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-6ADFEDDB·Framework v5.8·Pipeline v0.4·Evaluated 19 Aug 2026·OECD: 3.1 Basic medicine·Subfield: Molecular Biology·Basis: Full text·Type: Narrative review

A Protective Role of the NRF2-Keap1 Pathway in Maintaining Intestinal Barrier Function

Zhiyong Wen et al.Zhiyong Wen, Weihua Liu, Xing Li et al.·2019·10.1155/2019/1759149 ↗

Primary claim

NRF2 reduced intestinal mucosal injury by suppressing oxidative stress

Supported · consistent direction across multiple preclinical models, with little direct human or clinical evidence
In brief

A useful map of NRF2-mediated intestinal barrier mechanisms, constrained by one-sided, methodologically non-systematic evidence selection.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

Nrf2 (NF-E2-related factor 2) is a master regulator of cellular oxidative levels against environmental stresses. Nrf2 induces the expression of metabolic detoxification and antioxidant enzymes to eliminate reactive oxygen species (ROS). The gastrointestinal tract is a key source of ROS. Intestinal barrier is critical to maintain the healthy steady state of the human gastrointestinal tract. Nrf2 has been shown to play important roles in maintaining the integrity of intestinal mucosal barrier. Here, we made a systematic review on the roles of Nrf2 in maintaining intestinal barrier, including the following: (1) NRF2 reduced intestinal mucosal injury by suppressing oxidative stress; (2) NRF2 decreased intestinal inflammation by inhibiting the inflammatory pathway; (3) NRF2 affected intestinal tight junction proteins and apoptosis of cells to regulate intestinal permeability; (4) NRF2 affected T cell differentiation and functions; (5) the crossregulation between the KEAP1-NRF2 pathway and autophagy controlled intestinal oxidative stress.

Key Claims

Primary finding · Supported

NRF2 reduced intestinal mucosal injury by suppressing oxidative stress

consistent direction across multiple preclinical models, with little direct human or clinical evidence

Abstract claim 1; Section 2
Quote verified
Secondary · Supported

NRF2 decreased intestinal inflammation by inhibiting the inflammatory pathway

preclinical findings support reduced inflammation, but direct pathway inhibition remains unresolved against ROS-mediated effects

Abstract claim 2; Section 3
Quote verified
Secondary · Supported

NRF2 affected intestinal tight junction proteins and apoptosis of cells to regulate intestinal permeability

several animal models support directional effects, but evidence remains predominantly preclinical

Abstract claim 3; Section 4
Quote verified
Secondary · Tentative

NRF2 affected T cell differentiation and functions

conflicting activator studies and cytokine-based inference do not establish a unified intestinal T-cell mechanism

Abstract claim 4; Section 5
Quote verified
Secondary · Tentative

the crossregulation between the KEAP1-NRF2 pathway and autophagy controlled intestinal oxidative stress

mechanistic associations are summarized, while the crossregulation itself remains explicitly unresolved

Abstract claim 5; Section 6
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad coverage across barrier mechanisms

Sections 2–6 cover oxidative stress, inflammatory signaling, permeability, T-cell function, and autophagy, while Figure 1 places them in one mechanistic overview.

↳ Sections 2–6; Figure 1

#positioning

Multiple preclinical contexts summarized

Table 1 brings together colitis, burn, ischemia-reperfusion, sepsis, traumatic brain injury, and other models, showing that the reviewed relationship is not confined to one experiment type.

↳ Section 2; Table 1

#reporting

Clear mechanism-based navigation

The article's principal sections correspond directly to its five stated claims, allowing readers to locate the supporting studies and acknowledged uncertainties efficiently.

↳ Abstract; Sections 2–6

Limitations

#methodological rigour

Systematic label lacks review methods

The Abstract describes a systematic review, but the paper reports no databases, search terms, eligibility criteria, selection procedure, or study-quality appraisal.

↳ Abstract; absence of a review-methods section throughout the full text

#methodological rigour

Evidence synthesis remains one-sided

Sections 2–6 predominantly assemble studies supporting protective NRF2 effects. Constitutive-activation harms and oncogenesis are mentioned only in the Conclusion and are not substantively integrated into the synthesis.

↳ Sections 2–7

#reporting

Abstract overstates unresolved mechanisms

Claims about direct inflammatory inhibition, T-cell effects, and autophagy crossregulation are stated as findings in the Abstract, whereas Sections 3, 5, and 6 explicitly retain substantial uncertainty.

↳ Abstract claims 2, 4, and 5; Sections 3, 5, and 6

Does this match your read? Add your assessment ↓

Nabu Commentary

Table 1 and Figure 1 make the review useful as an entry point to NRF2-related intestinal barrier mechanisms across several preclinical contexts. The score is constrained by the absence of any systematic source-selection method despite the Abstract's study-type label. Sections 3, 5, and 6 also qualify mechanisms that the Abstract presents more definitively. Finally, the Conclusion acknowledges constitutive-activation and oncogenesis risks without integrating them into its therapeutic interpretation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.6±0.2

Contribution
2.6

The review consolidates oxidative stress, inflammation, permeability, T-cell, and autophagy mechanisms into one accessible account. Its advance remains limited because Sections 2–6 mostly restate individual studies without resolving their uncertainties or developing a new integrative framework.

Abstract; Sections 2–7; Figure 1

“more studies are needed to investigate this crossregulation”

Methodological Rigour
2.5

Mechanism-based sections, Table 1, and Figure 1 provide a followable structure and link claims to cited studies. Evidence selection is predominantly protective in direction, and no search, eligibility, selection, or appraisal method is reported despite the systematic-review label.

Abstract; Sections 2–6; Table 1; Figure 1

“Here, we made a systematic review”

Reporting
3.1

The five-section organization makes the argument easy to navigate, although awkward phrasing occasionally interrupts readability. More materially, definitive abstract claims about inflammation, T cells, and autophagy are not calibrated to the uncertainty stated in Sections 3, 5, and 6.

Abstract claims 2, 4, and 5; Sections 3, 5, and 6

“the exact mechanism remains largely unknown”

Positioning
2.8

The review engages 46 references across numerous experimental models and acknowledges uncertainty in several mechanisms. The conclusion mentions lethality and oncogenesis from constitutive pathway activation but does not trace those caveats through its intestinal therapeutic claim.

Sections 2–7; Table 1; Conclusion

“constitutive activation of Nrf2 in the upper digestive tract tissues can result in serious adverse effects”

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The study-type label is inconsistent with the reported review process: the Abstract claims a systematic review, while the body supplies no systematic method and describes the work as a summary. Several abstract claims are also more definitive than the uncertainty acknowledged in Sections 3, 5, and 6.

Research ConductClean

The article reports no original experiment, so ethics approval, preregistration, and data or code availability are not applicable; no research-conduct problem was demonstrated in the supplied text.

Flags: 0 declared / 5 total

Reference IntegrityClean

46 of 46 checkable references verified

46 references in manuscript 1 reference confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceSynthesis
Route to useSuggested
AdvanceConsolidates
BeneficiariesSmall
CitationsFWCI 4.4
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The claim is supported by controlled experiments in mouse models and cell lines, with only observational human tissue data and no interventional validation in people.

From the paper
“Nrf2 becomes a potential target in the treatment of multiple intestinal diseases induced by mucosal barrier injury”

The conclusion names a therapeutic use of the findings (Nrf2 as a drug target for intestinal diseases) but does not name who would act on them or in what setting.

Pathway

Drug developers and gastroenterologists could act on these findings by developing and testing Nrf2-inducing drugs to protect the intestinal barrier in IBD and related diseases.

Barrier

No human trials of Nrf2 activation for intestinal barrier injury exist, and the paper itself flags safety concerns including Keap1-knockout lethality and links to oncogenesis.

Evaluated 12 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets

    Arno R. Bourgonje, Damian Klóska, Anna Grochot‐Przeczek, et al. · 2023 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease

    Sem Geertsema, Arno R. Bourgonje, Raphael R. Fagundes, et al. · 2023 · Clinical medicine

    Primary claim

    Preclinical evidence supports targeted therapeutic modulation of the NRF2/Keap1 pathway in the gastrointestinal tract, albeit human evidence is scarce.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    No concerns
  3. The Nrf2 in the pathophysiology of the intestine: Molecular mechanisms and therapeutic implications for inflammatory bowel diseases

    Marta Piotrowska, Mikołaj Świerczyński, Jakub Fichna, et al. · 2020 · Clinical medicine

    Primary claim

    The Nrf2/Keap1 axis plays a crucial role in the development of gastrointestinal (GI) tract and the maintenance of its proper functionality.

    Supported
    Evidence Score
    2.8±0.2
    Reliability
    No concerns

How the rubric works →